Vitamin B6 Deficiency Presenting with New-Onset Epilepsy and Status Epilepticus in a Patient with Parkinson Disease
Neurol 94:e2605-e2607, Modica, J.S.,et al, 2020
Cognitive Change Following MPTP Exposure
Neurol 40:261-264, Stern,Y.,et al, 1990
Amyotrophic Lateral Sclerosis & its Association with Dementia, Parkinsonism & Other Neurological Disorders:A Review
Brain 104:217-247, Hudson,A.J., 1981
The Effect of Symptom Duration on Cognitive & Motor Performance in Parkinsonism
Neurol 29:951-956, Matthews,C.G.,et al, 1979
Complete Evaluation of Dementia: PET and MRI Correlation and Diagnosis for the Neuroradiologist
AJNR 42:998-1007, Oldan, J.D.,et al, 2021
The Parkinson Pandemic - A Call to Action
JAMA Neurol 75:9-10, Dorsey, E.R. & Bloem, B.R., 2018
Distinguishing Neuroimaging Features in Patients Presenting with Visual Hallucinations
AJNR 37:774-781, Winton-Brown, T.T.,et al, 2016
Clinical, Genetic, and Radiological Features of Extrapyramidal Movement Disorders in Mitochondrial Disease
JAMA Neurol 73:668-674, Martikainen, M.H.,et al, 2016
Non-Alzheimers Dementia 2 Lewy Body Dementias
Lancet 386:1683-1697, Walker, Z.,et al, 2015
Palliative Care and Neurology
Neurol 83:561-567, Boersma, I.,et al, 2014
Incidence and Pathology of Synucleinopathies and Tauopathies Related to Parkinsonism
JAMA Neurol 70:859-866, Savica, R.,et al, 2013
Patterns and Trends in Antipsychotic Prescribing for Parkinson Disease Psychosis
Arch Neurol 68:899-904, Weintraub, D.,et al, 2011
Dementia and Survival in Parkinson Disease: A 12-Year Population Study
Neurol 70:1017-1022, Buter,T.C.,et al, 2008
Quetiapine for Agitation or Psychosis in Patients with Dementia and Parkinsonism
Neurol 68:1356-1363, Kurlan,R.,et al, 2007
Predictors of Fitness to Drive in People With Parkinson Disease
Neurol 69:1434-1441, Devos,H.,et al, 2007
Practice Parameter: Evaluation and Treatment of Depression, Psychosis, and Dementia in Parkinson Disease (An Evidence-Based Review)
Neurol 66:996-1002, Miyasaki,J.M.,et al, 2006
Donepezil for Dementia in Parkinsons Disease: A Randomised, Double Blind, Placebo Controlled, Crossover Study
JNNP 76:934-939,903, Ravina,B.,et al, 2005
Sudden Uncontrollable Somnolence and Medication Use in Parkinson Disease
Arch Neurol 62:1242-1248, Avorn,J.,et al, 2005
Rivastigmine for Dementia Associated with Parkinson's Disease
NEJM 351:2509-2518,2547, Emre,M.,et al, 2004
Nonmotor Fluctuations in Parkinson's Disease
Neurol 59:408-413, Witjas,T.,et al, 2002
Effects of Bilateral Subthalamic Stimulation on Cognitive Function in Parkinson Disease
Arch Neurol 58:1223-1227,1205, Alegret,M.,et al, 2001
The Nonmotor Problems of Parkinson's Disease
The Neurologist 6:18-27, Friedman,J.H.&Fernandez,H.H., 2000
What Contributes to Quality of Life in Patients with Parkinson's Disease?
JNNP 69:308-312,289, Schrag,A. et al, 2000
Diagnostic Criteria for Parkinson Disease
Arch Neurol 56:33-39, Gelb,D.J.,et al, 1999
Efficacy, Safety, and Tolerance of the Non-Ergoline Dopamine Agonist Pramipexole in the Treatment of Advanced Parkinson's Disease:A Double Blind, Placebo Controlled, Randomised, Multicentre Study
JNNP 66:436-441, Pinter,M.M.,et al, 1999
Nuclear Medicine in Neurology and Psychiatry
Lancet 354:1107-1111, Costa,D.C.,et al, 1999
Assessment of Motor Function After Stereotactic Pallidotomy
Neurol 50:266-270, Ondo,W.G.,et al, 1998
Postmenopausal Estrogen Use and Parkinson's Disease with and without Dementia
Neurol 50:1141-1143, Marder,K.,et al, 1998
An Unusual Case of Creutzfeldt-Jakob Disease
Neurol 51:617-619, Vingerhoets,F.J.G.,et al, 1998
Hereditary Form of Parkinsonism-Dementia
Ann Neurol 43:768-781, Muenter,M.D.,et al, 1998
Neuropsychological Consequences of Posteroventral Pallidotomy for the Treatment of Parkinson's Disease
Neurol 51:207-215, Trepanier,L.L.,et al, 1998
Cognitive Functioning After Pallidotomy for Refractory Parkinson's Disease
JNNP 65:150-154, 1481998., Perrine,K.,et al, 1998
Motor, Cognitive, and Behavioral Performance Following Unilateral Ventroposterior Pallidotomy for Parkinson Disease
Arch Neurol 55:1201-1208, Masterman,D.,et al, 1998
Olfactory Dysfunction in Guamanian ALS,Parkinsonism,and Dementia
Neurol 51:1672-1677, Ahlskog,J.E.,et al, 1998
Safety and Efficacy of Pramipexole in Early Parkinson Disease
Parkinson Study Group, JAMA 278:125-1301997., , 1997
Frequency of Dementia in Parkinson Disease
Arch Neurol 42:428-431, Aarsland,D.,et al, 1996
Encephalopathy with Parkinsonian Features in Children Following Bone Marrow Transplantations and High-Dose Amphotericin B
Ann Neurol 37:810-814, Mott,S.H.,et al, 1995
Neurological Sequelae of Cyanide Intoxication-The Patterns of Clinical MRI & Pet Findings
Ann Neurol 38:825-828, Rosenow,F.,et al, 1995
Decreased SPECT[123I]B-CIT Striatal Uptake Correlates with Symptom Severity in Parkinson's Disease
Ann Neurol 38:589-598, Seibyl,J.P.,et al, 1995
The Relationship of Essential Tremor to Other Movement Disorders:Report on 678 Patients
Ann Neurol 35, 717-7231994., Koller,W.C.,et al, 1994
Reversal of Amphotericin-B-Related Encephalopathy
Neurol 44:1183-1184, Balmaceda,C.M.,et al, 1994
Extrapyramidalism in Alzheimer's Disease:Prevalence, Psychiatric and Neuropsychological Correlates
JNNP 57:1503-1509, Merello,M.,et al, 1994
Post-Traumatic Movement Disorders:Central and Peripheral Mechanisms
Neurol 44:2006-2014, Jankovic,J., 1994
A Clinicopathologic Study of 100 Cases of Parkinson's Disease
Arch Neurol 50:140-148, Hughes,A.J.,et al, 1993
Subcortical Dementia
BMJ 307:1-2, Dunne,F.J., 1993
Delayed Encephalopathy after Acute Carbon Monoxide Intoxication:MR Imaging Features & Cerebral White Matter Lesions
Radiology 184:117-122, Chang,K.H.,et al, 1992
Cerebral Glucose Metabolism in Parkinson's Disease with and without Dementia
Arch Neurol 49:1262-1268, Peppard,R.F.,et al, 1992
Lesions of Basal Ganglia Due to Disulfiram Neurotoxicity
JNNP 55:925-929, Laplane,D.,et al, 1992
Driving in Parkinson's Disease
Neurol 41:517-520, Dubinsky,R.M.,et al, 1991